Journal article

Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects

Christina M Lill, Tian Liu, Brit-Maren M Schjeide, Johannes T Roehr, Denis A Akkad, Vincent Damotte, Antonio Alcina, Miguel A Ortiz, Rafa Arroyo, Aitzkoa Lopez de lapuente, Paul Blaschke, Alexander Winkelmann, Lisa-Ann Gerdes, Felix Luessi, Oscar Fernadez, Guillermo Izquierdo, Alfredo Antigueedad, Sabine Hoffjan, Isabelle Cournu-Rebeix, Silvana Gromoeller Show all

JOURNAL OF MEDICAL GENETICS | BMJ PUBLISHING GROUP | Published : 2012

Grants

Awarded by BMBF


Awarded by Innovation Fund of the Max Planck Society


Awarded by European Framework


Awarded by Swedish Research Council


Awarded by Ministerio de Ciencia e Innovacion (MCINN)-Fondos Europeos de Desarrollo Regional (FEDER)


Awarded by EU by the Instituto de Salud Carlos III


Funding Acknowledgements

This project was funded by grants from the German Ministry for Education and Research (BMBF) and German Research Foundation (DFG; to FZ), the BMBF and the Cure Alzheimer's Fund (to LB (Berlin)), the Walter- and Ilse-Rose-Stiftung (to H-PH and OA), the BMBF (grant NBL3 to UKZ; grant 01UW0808 to UL, and ES-T), and the Innovation Fund of the Max Planck Society (M.FE.A.BILD0002 to UL). This project was supported by INSERM, ARSEP, AFM and GIS-IBISA. CML was supported by the Fidelity Biosciences Research Initiative. CC was supported by the European Framework FP7/2007-2013 (no 212877 UEPHA*MS). LB (Stockholm) was supported by the Swedish Research Council (Grant 521-2007-2892), Swedish Brain Power, and an Alexander von Humboldt Research Award. AA [Granada] and FM were supported by the Ministerio de Ciencia e Innovacion (MCINN)-Fondos Europeos de Desarrollo Regional (FEDER) [grant number SAF2009-11491] and EU by the Instituto de Salud Carlos III, FIS10/1985.Dr LA Gerdes reports to have received travel expenses and personal compensation from Merck Serono, Teva Pharmaceutical Industries, Bayer Schering Pharma, Novartis, and Biogen Idec. Dr T Kumpfel reports to have received travel expenses and personal compensations from Bayer Schering Pharmacy, Teva, Merck-Serono, Novartis, Sanofi-Aventis and Biogen-Idec as well as grant support from Bayer-Schering AG. None of the other authors reports any disclosures.